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The peroxisome proliferator-activated receptor α (PPARα, or NR1C1) is a nuclear hormone receptor activated
by a structurally diverse array of synthetic chemicals known as peroxisome proliferators. Endogenous
activation of PPARα in liver has also been observed in certain gene knockout mouse models of lipid metabolism,
implying the existence of enzymes that either generate (synthesize) or degrade endogenous PPARα agonists.
For example, substrates involved in fatty acid oxidation can function as PPARα ligands. PPARα serves as a
xenobiotic and lipid sensor to regulate energy combustion, hepatic steatosis, lipoprotein synthesis,
inflammation and liver cancer. Mainly, PPARα modulates the activities of all three fatty acid oxidation systems,
namely mitochondrial and peroxisomal β-oxidation and microsomal ω-oxidation, and thus plays a key role in
energy expenditure. Sustained activation of PPARα by either exogenous or endogenous agonists leads to
the development of hepatocellular carcinoma resulting from sustained oxidative and possibly endoplasmic
reticulum stress and liver cell proliferation. PPARα requires transcription coactivator PPAR-binding protein
(PBP)/mediator subunit 1(MED1) for its transcriptional activity.
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Introduction
Peroxisome proliferator-activated receptor (PPAR) α
(NR1C1), β/δ (NR1C2), and γ (NR1C3), are
ligand-activated transcription factors that are members
of the nuclear-hormone receptor (NR) superfamily
[Bookout et al., 2006; Issemann and Green, 1990;
Michalik et al., 2006].The foundation for the discovery
and designation of the PPAR subfamily of nuclear
receptors in the 1990s [Dreyer et al., 1992; Issemann
and Green, 1990], is the cumulative work over the
preceding 25 years with peroxisome proliferators (PPs),
a group of structurally diverse chemicals that lower serum
lipids, and induce massive proliferation of peroxisomes
in liver cells, with associated coordinated transcriptional
activation of peroxisomal fatty acid β-oxidation system
genes [Reddy et al., 1980; Reddy and Krishnakantha,
1975; Reddy et al., 1976; Reddy et al., 1986b]. A receptor
for these chemicals was originally postulated in the mid
1980s [Lalwani et al., 1987; Lalwani et al., 1983; Rao and
Reddy, 1987; Reddy and Lalwani, 1983] to account for
the cell-specific highly reproducible pleiotropic responses
[Reddy and Chu, 1996]. Chronic exposure to PPs results
in the development of liver cancer in rats and mice,
although these agents are nonmutagenic [Rao and
Reddy, 1987; Reddy et al., 1980; Reddy et al., 1976]. It
was therefore envisaged that a receptor-mediated
mechanism is responsible for both the immediate and
long-term effects of PPs, including the development of
liver cancer [Rao and Reddy, 1987; Reddy and Chu,
1996]. A search for a receptor for these ligands was
underway [Lalwani et al., 1987], and this culminated in
the cloning of a receptor activated by PPs by Issemann
and Green [Issemann and Green, 1990].This receptor
was appropriately designated PP-Activated Receptor or
PPAR [Issemann and Green, 1990]. Subsequent
identification of two other members of this family, namely
PPARβ/δ and PPARγ, resulted in designating the original
receptor activated by PPs as PPARα [Dreyer et al., 1992].
Gene knockout studies in mice have unequivocally
established that PPARα is indeed responsible for the
PP-induced array of pleiotropic responses including liver
cancer in rodents [Lee et al., 1995].
All three members of the PPAR subfamily function as
sensors for fatty acids and fatty acid derivatives, and thus
control important metabolic pathways involved in lipid
and energy metabolism [Chawla et al., 2001; Krey et al.,
1997]. In the liver, PPARα is activated by synthetic PPs
and by both saturated and polyunsaturated fatty acids
and their derivatives, and regulates fatty acid oxidation
systems to increase energy combustion. PPARα also
plays a role in lipoprotein synthesis, inflammatory
responses and the development of cancer in the rodent
liver [Lee et al., 1995; Mei et al., 2009; Mukherjee et al.,
2008]. PPARβ/δ also enhances fatty acid catabolism and
energy uncoupling in skeletal muscle and adipose tissue
as well as recently shown in the liver where it may
participate in the hepatic response to starvation
[Sanderson et al., 2009;Wang et al., 2003]. Additionally,
PPARβ/δ may play a protective role in the liver by
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liver damage [Nagasawa et al., 2006; Shan et al., 2008a;
Shan et al., 2008b].Together, PPARα and PPARβ/δ are
active participants in energy burning, whereas PPARγ,
which has two isoforms, PPARγ1 and PPARγ2, is critical
in regulating adipocyte differentiation and energy storage
by adipocytes [Kliewer et al., 2001;Tontonoz et al., 1994;
Zhu et al., 1995]. PPARγ can also induce lipid
accumulation in other cell types, such as hepatocytes,
when overexpressed [Yu et al., 2003]. In essence, PPARγ
regulates anabolic lipid metabolism, while PPARα and
PPARβ/δ function as catabolic regulators of energy
[Chawla et al., 1994;Tontonoz et al., 1994;Wang et al.,
2003].
The PPARα gene and protein structure
The human PPARα (NR1C1) gene, which spans ~93.2
kb, is located on chromosome 22 at position 22q12-q13.1
and it encodes a protein of 468 amino acids [Sher et al.,
1993].The mouse PPARα gene, located on chromosome
15E2, also encodes a protein of 468 amino acids
[Issemann and Green, 1990]. As in the mouse, the human
PPARα gene encoded mRNA is derived from 8 exons
with a 5' untranslated region encoded by exons 1, 2, and
part of exon 3 [Desvergne and Wahli, 1999; Sher et al.,
1993].The remainder of exon 3 and exons 4-8 contribute
to the coding region of PPARα [Desvergne and Wahli,
1999; Sher et al., 1993].The last 232 bp of exon 8
contribute to the 3'-untranslated region [Vohl et al., 2000].
PPARα shares common structural characteristics with
the other members of the NR family [Desvergne and
Wahli, 1999]. It displays five distinguishable domains
designated the A/B, C, D, E and F domains, respectively
(Figure 1).The PPARα N-terminal A/B domain contains
an activation function-1 (AF-1) region.This region has a
low level of basal transcriptional activity and functions
independent of ligand-binding [Desvergne and Wahli,
1999].The specificity of gene transcription is granted by
the isoform-specific sequence of the A/B domain of the
receptor [Hummasti and Tontonoz, 2006]. Chimeric
proteins generated by fusion with the A/B domains of
other receptor proteins attenuate the specificity of target
gene activation [Hummasti and Tontonoz, 2006].The A/B
domain is followed by a DNA-binding domain (C)
encompassing amino acids 101-166 in the human that
contains two very highly conserved zinc finger motifs and
architectural elements capable of sequence-specific
binding to DNA [Desvergne and Wahli, 1999].
Next to the DNA-binding domain is a flexible hinge domain
(D), which connects the DNA-binding domain and the
ligand-binding domain (E) [Desvergne and Wahli, 1999].
This hinge region binds corepressor proteins, with the
characteristic LXXXIXXXL repressor motif, to the receptor
in its quiescent, unliganded state [Dowell et al., 1999].
The corepressor-binding site partly overlaps with the
coactivator-binding site.The ligand binding domain in the
human PPARα protein extends from amino acids 280-468
and contains an activation function-2 (AF-2) region
composed of two α-helices flanking one four-stranded
β-sheet [Desvergne and Wahli, 1999].The AF-2 domain
is repressed until ligand-binding occurs. Following
ligand-binding, the AF-2 domain undergoes a
conformational shift, which allows the formation of
hydrogen bonds between Tyr-314 and Tyr-464, as well
as the formation of a charge clamp between Glu-462 and
Lys-292 [Xu et al., 2001].This conformational change in
the protein allows interaction of the receptor with the
LXXLL (L, leucine; X, any amino acid) motifs located in
coactivator proteins [Xu et al., 2001]. PPARα, like other
nuclear receptors, will undergo conformational adjustment
upon binding to a ligand to achieve the coregulator
exchanges and activation of the target genes [Xu et al.,
2001].
The PPAR ligand binding cavity, with a total volume of
1300 to 1400 A°, is larger than that found in other NRs
[Desvergne and Wahli, 1999; Xu et al., 2001]. It is defined
by 34 amino acid residues and 80% of these residues
are highly conserved across the three PPAR subtypes
[Dreyer et al., 1992]. PPARα and PPARγ ligand binding
cavities are similar in size, but the PPARβ/δ pocket is
significantly narrower in the region adjacent to the AF-2
helix and does not readily accommodate bulky polar
heads [Cronet et al., 2001]. Similarity between PPARα
and PPARγ ligand binding pockets may account for some
degree of flexibility in ligand-receptor interaction between
these two isoforms and their ability to bind a wide range
of synthetic and natural lipophilic compounds [Xu et al.,
2001]. Comparison of the crystal structures of the ligand
binding domains showed that a single amino acid, tyrosine
314 in PPARα and histidine 323 in PPARγ, accounts for
the subtype selectivity for classes of ligands [Xu et al.,
2001].The PPARα pocket is more lipophilic than that of
PPARγ and this may account for the greater affinity of
PPARα to bind the more lipophilic-saturated fatty acids
[Xu et al., 2001].
Expression of PPARα
PPARα belongs to the type II nuclear receptor family and
like the other two PPAR isotypes, is localized in the
nucleus.This differs from type I nuclear receptors, which
are cytosolic and translocate to the nucleus upon
ligand-binding. High levels of PPARα expression are
found in tissues with active fatty acid catabolism, such
as liver, heart, kidney, brown adipose tissue, muscle,
small intestine and the large intestine [Bookout et al.,
2006; Braissant et al., 1996; Issemann and Green, 1990].
Similar tissue expression profiles of PPARα have been
found in rodents and human [Bookout et al., 2006].
PPARα exerts a dominant role in fatty acid catabolism
and ketone body synthesis in the liver [Kersten et al.,
1999]. PPARβ/δ also participates in energy catabolism,
but its effects are more prominent in muscle and heart,
though it also regulates some genes in the liver
[Sanderson et al., 2009]. In contrast, PPARγ is expressed
abundantly in white adipose tissue, where it is involved
in lipid storage and in brown adipose tissue, where it
participates in energy dissipation [Tontonoz et al., 1994].
While PPARα regulates many target genes, the
expression of the PPARα gene itself is under the control
of other transcription factors [Pineda Torra et al., 2002].
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Review Pleiotropic responses of PPARαFigure 1.  Schematic view of the PPARα structure. Domain structure of the PPARα protein (A) with the ligand-independent activation function 1
(AF1) domain or A/B domain shown in blue, the DNA-binding domain (DBD) or C domain shown in yellow, the hinge or D domain shown in orange,
and the ligand-binding domain (LBD) or E domain together with the activation function 2 (AF2) or F domain shown in green. (B) Schematic representation
of the PPARα protein with phosphorylation sites labeled with yellow stars, the corepressor site labeled with a red circle, and the coactivator binding
site shown with a blue hexagon.
In rodents, PPARα is regulated by various physiological
conditions such as stress, hormones (including growth
hormone), glucocorticoids, insulin, and leptin [Inoue et
al., 2008; Lee et al., 2002]. PPARα expression is also
reported to be related to aging [Poynter and Daynes,
1998], and is induced during brown adipocyte
differentiation [Kelly et al., 1998]. Expression levels of
PPARα in mouse liver are increased during starvation
and this leads to enhanced expression of PPARα target
genes in liver to catabolize influxed fatty acids [Kersten
et al., 1999]. Human PPARα is also regulated at the
transcriptional level by nuclear receptors, such as
hepatocyte nuclear factor 4 (HNF4), and chicken
ovalbumin upstream promoter-transcription factor II
(COUP-TFII) [Pineda Torra et al., 2002]. HNF4 positively
regulates PPARα expression via a direct repeat 1 (DR1)
element, which is composed of the consensus sequence
AGG(A/T)CA separated with a single nucleotide spacing
between two repeats [Pineda Torra et al., 2002]. On the
other hand, the DR1 element in the human PPARα
promoter is antagonized by the orphan receptor
COUP-TFII [Pineda Torra et al., 2002]. Furthermore,
PPARα appears to modulate its own expression [Corton
et al., 2000]. In human liver, PPARα mRNA levels may
vary significantly among individuals and are considered
lower than the levels noted in rodent livers, but this may
in part be related to variations in liver sample procurement
for the frozen archival liver bank [Palmer et al., 1998;
Walgren et al., 2000]. PPARα transcript levels are also
induced during macrophage differentiation by high
glucose levels [Rigamonti et al., 2008]. PPARα is also
regulated by the ubiquitin proteasomal degradation
system [Genini et al., 2008].
Posttranslational modifications
A truncated PPARα isoform resulting from a
posttranslational exon skipping mechanism has been
detected in human, swine, and jerboas [El Kebbaj et al.,
2009; Gervois et al., 1999].This truncated form harbors
dominant negative transcriptional repressive activity on
PPARα. In addition, PPARα activity is regulated by
posttranslational modifications such as phosphorylation
(Figure 1). PPARα was first shown to be phosphorylated
in primary rat adipocytes in culture [Shalev et al., 1996].
Insulin treatment increases PPARα phosphorylation and
nearly doubles its transcriptional activity in CV-1 and
HepG2 cells in culture [Shalev et al., 1996].This
insulin-mediated phosphorylation of PPARα involves
amino acids Ser12 and Ser21 [Juge-Aubry et al., 1999].
Stress stimuli exert an increase in PPARα
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p38 mitogen-activated protein kinase (MAPK) pathway
[Barger et al., 2001]. p38 MAPK phosphorylates Ser 6,
12 and 21 residues located within the N-terminal A/B
domain of the protein and this phosphorylation
significantly enhanced ligand-dependent transactivation
of PPARα [Barger et al., 2001]. PPARα is also reported
to be phosphorylated by protein kinase C (PKC). Inhibition
of PKC activity impairs ligand-activated PPARα
transactivation activity, but enhances PPARα
transrepression activity. Purified PPARα protein is
phosphorylated in vitro by recombinant PKCα and -βII.
These data demonstrate that the PKC signaling pathway
may act as a molecular switch for the transactivation and
transrepression properties of PPARα, which involve
phosphorylation of Ser179 and Ser230 [Blanquart et al.,
2004].This PKC phosphorylation of PPARα is believed
to play an important role in statin-mediated acute
anti-inflammatory effects, though the importance of
phosphorylation in PPARα signaling has never been
clearly demonstrated in vivo [Paumelle et al., 2006].
PPARα ligands
PPARα ligands fall into two general categories:synthetic
xenobiotics (exogenous) and biological molecules
(endogenous). Synthetic ligands, referred to as PPs,
include hypolipidemic drugs such as clofibrate,
fenofibrate, gemfibrozil, bezafibrate, ciprofibrate,
nafenopin, methyl clofenapate, tibric acid, and Wy-14,643
(pirinixic acid) used in the treatment of dyslipidemias, and
industrial phthalate-monoester plasticizers, such as
di-(2-ethylhexyl)-phthalate (DEHP), and di-(2-ethylhexyl)
adipate (DEHA) used in the manufacture of polyvinyl
chloride plastics [Lalwani et al., 1983; Maloney and
Waxman, 1999]. Certain herbicides, pesticides, industrial
solvents, food flavoring agents, and leukotriene D4
receptor antagonists also function as PPARα ligands
[Maloney and Waxman, 1999].These structurally-diverse
chemicals induce highly reproducible and similar
pleiotropic responses in the rat and mouse liver.
Proliferation of peroxisomes in liver parenchymal cells
and profound transcriptional activation of fatty acid
oxidation system genes are the hallmarks of PP-induced
pleiotropic responses in the rat and mouse liver.
Endogenous or naturally-occurring biological molecules
that serve as PPARα ligands include fatty acids and fatty
acid derivatives (Figure 2) [Devchand et al., 1996;
Hostetler et al., 2005]. Endogenous PPARα activators,
in most part, have been identified using in vitro
approaches [Forman et al., 1997; Gottlicher et al., 1992;
Hostetler et al., 2005; Krey et al., 1997]. Both dietary
saturated and unsaturated fatty acids function as direct
ligands for PPARα [Hostetler et al., 2005]. Alternately,
the ultimate ligands for this receptor may be generated
during fatty acid catabolism and new fatty acid synthesis
in vivo [Chakravarthy et al., 2009] (Figure 2). Several
enzymes such as the 8-, 12-, 15- and 5-lipoxygeneases,
the cyclooxygenases and cytochrome P450s utilize fatty
acids as substrates to produce putative PPARα ligands
[Brash, 1999; Crisafulli and Cuzzocrea, 2009; Ng et al.,
2007]. Although many synthetic ligands activate PPARα
efficiently, it appears that PPARα has evolved primarily
for lipid sensing to regulate energy combustion [Reddy,
2004; Reddy and Rao, 2006].
Evidence suggests that PPARα senses certain
endogenous lipid metabolic intermediates as ligands and
participates in their metabolism (degradation) by inducing
downstream lipid metabolism-related genes [Fan et al.,
1998].The first in vivo evidence came from studies with
fatty acyl-CoA oxidase 1 (ACOX1) gene disrupted mice,
in that mice deficient in this first and rate-limiting enzyme
of the fatty acid β-oxidation system reveal profound
activation of PPARα in liver [Fan et al., 1996; Fan et al.,
1998;Yeldandi et al., 2000]. Animals deficient for the
ACOX1 have high levels of the very long chain fatty acids
and since very-long chain fatty acyl-CoAs are incapable
of entering the fatty acid oxidation pathway due to ACOX1
deficiency, these unmetabolized substrates act as ligands
to hyperactivate PPARα [Fan et al., 1998;Yeldandi et
al., 2000]. Recent studies with other gene knockout




(D-PBE/MFP2) and sterol carrier protein x (SCPx) are
necessary for the degradative metabolism of
endogenously-generated PPARα ligands [Ellinghaus et
al., 1999; Fan et al., 1998; Jia et al., 2003; Martens et al.,
2008; Qi et al., 1999a; Seedorf et al., 1998], while other
enzymes such as fatty-acid synthase (FAS), fatty
acyl-CoA synthetase (FACS) and certain lipoxygenases
(LO), are required for PPARα ligand generation
[Chakravarthy et al., 2009; Martin et al., 2000;Yu and
Reddy, 2007]. It is implied that substrates of ACOX1,
such as very long-chain fatty acyl-CoAs, when left
unmetabolized in the absence of this enzyme, function
as potent endogenous ligands of PPARα [Fan et al., 1998;
Yeldandi et al., 2000]. It is known that long-chain acyl-CoA
esters can act as regulatory molecules in vivo [Faergeman
and Knudsen, 1997; Fan et al., 1996; Fan et al., 1998;
Hostetler et al., 2005]. PPARα exhibits high affinity for
the CoA thioesters of the common (C20-C24) very long
chain fatty acids and these CoA thioesters of very-long
chain and branched-chain fatty acids are more potent
PPARα ligands than the free fatty acids [Hostetler et al.,
2005]. Further evidence that fatty acids are not the direct
in vivo ligands for PPARα comes from mice with disrupted
fatty acyl-CoA synthetase gene [Li et al., 2009]. Fatty
acyl-CoA synthetases activate long-chain fatty acids to
acyl-CoAs, thereby providing substrates for downstream
fatty acid β-oxidation pathways [Li et al., 2009]. Mice with
a disrupted fatty acyl-CoA synthetase 1 gene [Li et al.,
2009], or deficient for the adrenoleukodystrophy protein
gene (X-ALD) [Heinzer et al., 2003; Reddy and
Hashimoto, 2001], fail to convert fatty acids to acyl-CoAs
to serve as substrates for fatty acid β-oxidation vis à vis
ligands for PPARα [Heinzer et al., 2003; Li et al., 2009].
If long-chain fatty acids function as PPARα ligands in
vivo, one would have expected increased PPARα target
gene activation in X-ALD and fatty acyl-CoA synthetase
null mice, but that does not appear to be the case in these
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Review Pleiotropic responses of PPARαFigure 2.  Biological ligands of PPARα. Diagram illustrating different known biological ligands of PPARα. Metabolic sources for ligands are grouped
in the boxes together with ligand generating enzymes marked with an asterisk, ligands marked with a square and ligand degrading enzymes marked
with a triangle.The PPARα and RXRα heterodimer are shown bound to a PPRE sequence in the promoter of a target gene with associated coactivator
proteins forming a complex with the cellular transcription machinery.
null livers [Heinzer et al., 2003; Li et al., 2009]. Failure to
induce peroxisome proliferation in liver by dietary lipid
overload also indicates that fatty acids per se are not
effective PPARα ligands [Fan et al., 1998].
Experiments with liver-specific inactivation of fatty-acid
synthase (FAS) suggest that products of FAS serve as
endogenous activators of PPARα in adult liver
[Chakravarthy et al., 2007]. FAS-deficient mice reveal a
phenotype resembling PPARα deficiency [Chakravarthy
et al., 2007]. Recently, it has been demonstrated that
FAS generates
1-palmityl-2-oleolyl-sn-glycerol-3-phosphocholine
(16:0/18:1-GPC), which appears to be a physiologically
relevant PPARα ligand [Chakravarthy et al., 2009].
Leukotriene B4 (LTB4) is another well known putative
PPARα ligand, which connects the receptor to
inflammation and immune responses. 19- and
20-hydroxyeicosatetraenoic acid (19- and 20-HETE) are
the major products of cytochrome P450 catalyzed
conversion of arachidonic acid and play roles in the
cardiovascular system, kidney function, cellular
proliferation and inflammation. HETEs bind to and activate
PPARα in HepG2 cells transfected with human PPARα,
but do not show any transactivation activity when the cells
are transfected with the unrelated nuclear receptor TRβ
[Ng et al., 2007]. Oleylethanolamide (OEA), a
naturally-occurring lipid has been identified as a high
affinity PPARα ligand regulating PPARα activity and lipid
metabolism. Finding a way of regulating PPARα activity
through modulating endogenous ligand, and therefore
achieving control of energy metabolism and body weight,
may have the potential to generate new therapies.
A high degree of interest presently exists in discovering
new partial agonists of PPARα and of other PPAR
isoforms that are selective for beneficial effects of PPAR
activation and avoid problems with dose-related toxicity
and other negative side effects of PPAR activation [Chang
et al., 2007]. Direct glucose binding with the receptor has
also been shown to occur and may play an important
regulatory role in PPARα activity, particularly in the setting
of diabetes [Hostetler et al., 2008].
PPARα agonists, including fibrates such as fenofibrate,
gemfibrozil and less commonly clofibrate, have been in
use for several decades as therapeutic agents to
decrease plasma levels of triglycerides and VLDL by
enhancing lipid uptake and catabolism and to increase
plasma levels of HDL-C [Bays and Stein, 2003; Lefebvre
et al., 2006; Marx et al., 2004].The fibrate class of PPARα
ligands increase the production in the liver of the
apolipoproteins A-I and A-II, which are major components
of HDL-C [Bays and Stein, 2003].The search for agents
that display potent and selective binding to the PPARα
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coactivators is expected to result in the identification of
new classes of ligands [Kane et al., 2009].These novel
ligands, including LY518674, a novel PPARα ligand
recently reported by Nissen et al., have the traditional
benefits of reducing serum triglycerides and increasing
serum HDL-C, but may confer additional benefits such
as reduction of serum LDL-C, especially when paired with
other treatments. Novel therapeutics such as this may
hold the key to better treatments for lipid disorders such
as atherogenic dyslipidemia, which lead to other metabolic
and cardiac problems [Nissen et al., 2007]. Other current
therapeutic benefits of potential PPARα agonists are
under investigation for use in the prevention of
atherosclerosis, cardiomyopathies, ischemia-reperfusion
injuries, prevention of angiogenesis, anti-proliferation of
tumorigenic cells and others [Bulhak et al., 2009; Crisafulli
and Cuzzocrea, 2009; Gizard et al., 2008;
Massip-Salcedo et al., 2008; Panigrahy et al., 2008; Patel
et al., 2009; Ramanan et al., 2008; Staels et al., 2008;
Wang et al., 2009].
Other PPARα ligands with environmental impact, in
particular phthalate ester plasticizers widely used in the
manufacture of polyvinyl chloride plastics, and industrial
solvents such as trichloroethylene have been in use for
over 50 years.These are known contaminants of ground
water and estuaries, but the impact on human health is
unclear. More recently, certain herbicides have been
shown to function as PPARα ligands, implying that these
agents also constitute a major category of environmental
contaminants that can activate this receptor, and thus
raising issues about long-term or lifelong exposure.
PPARα heterodimerization with RXR,
binding to DNA elements and
PPARα-regulated genes
PPARα, like many non-steroid members of the NR family,
functions as an obligate heterodimer with another nuclear
receptor, retinoid X receptor (RXR; NR2B) [Kliewer et al.,
1992].The PPARα/RXR heterodimers can form
independent of the PPARα ligand and these unliganded
heterodimers recruit corepressor protein complex and
inhibit target gene transcription [DiRenzo et al., 1997].
Upon ligand binding, the corepressor complex is released
from the PPARα/RXR heterodimer, and the coactivator
complexes will be recruited to the promoter region of
target genes to initiate transcription [Dowell et al., 1999].
The PPARα/RXR heterodimers bind to a specific DNA
sequence element called a peroxisome proliferator
response element (PPRE), which was initially
characterized using the PPAR responsive promoter of
the rat Acox1 gene [Chandra et al., 2008; Kliewer et al.,
1992; Osumi et al., 1991;Tugwood et al., 1992; van der
Meer et al., 2010].This PPRE element is located in the
promoter region of target genes [Tugwood et al., 1992;
van der Meer et al., 2010; Zhang et al., 1992].The PPRE
is of the direct repeat 1 (DR1) category, which is
composed of two copies of the consensus hexamer
sequence AGG(A/T)CA separated by a single base pair
(Figure 2). Neither PPARα homodimers nor monomers
bind to the PPRE. PPARα target genes usually contain
one or more PPRE in the promoter and preferentially bind
PPARα/RXR heterodimers [Chu et al., 1995;Tugwood
et al., 1992]. Occasionally, PPRE may be in the proximal
transcribed regions of certain target genes [Di-Poi et al.,
2002].The PPRE element contains an additional AACT
motif positioned 5’ to the DR-1 [Juge-Aubry et al., 1997].
This upstream extended hexamer of the DR1 interacts
with PPARs, whereas the downstream hexamer is known
to interact with RXR of the PPAR/RXR heterodimer
[Desvergne and Wahli, 1999; Juge-Aubry et al., 1999].
Of the three PPARs, PPARγ binds more strongly than do
PPARα and PPARβ/δ, implying that conservation of the
5’-flanking extension is more important for the binding of
PPARα and PPARβ/δ [Juge-Aubry et al., 1997].The
nature of this upstream extension may confer isotype
specificity [IJpenberg et al., 1997].
The presence of PPRE upstream of the fatty acyl-CoA
oxidase 1 (ACOX1) gene [Tugwood et al., 1992], and
peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA
dehydrogenase (L-PBE) gene [Zhang et al., 1992] were
the first described. Interestingly, these were the first two
genes identified to be transcriptionally activated by PPs
[Reddy et al., 1986a; Reddy and Hashimoto, 2001;
Tugwood et al., 1992; Zhang et al., 1992]. Over the years,
many other genes that possess PPREs have been
characterized as PPARα target genes (Supplementary
File 1 and Supplementary File 2). cDNA microarray
profiling and comparative proteomic data have revealed
several known PPARα target genes and some new genes
that are upregulated in liver by the PPARα ligand,
Wy-14,643 [Cherkaoui-Malki et al., 2001; Chu et al., 2004;
Kane et al., 2009; Nielsen et al., 2006].These fall into
several functional categories including lipid metabolism,
xenobiotic metabolism, inflammation and others.
RXR, the heterodimerization partner of PPARs, is also a
partner of many other NRs [Bugge et al., 1992;
Juge-Aubry et al., 1995; Mangelsdorf et al., 1995].This
promiscuous centrality of RXR in NR functioning, raises
the possibility of competition between NRs for this
common binding partner [Juge-Aubry et al., 1995].
Reciprocal negative interaction between the PPARα and
thyroid hormone receptor signaling pathways is indirect,
in that it is mostly due to sequestration of RXR, the
common heterodimeric partner [Chu et al., 1995;
Juge-Aubry et al., 1995]. A similar competition can also
occur among PPAR isotypes with RXR in different cell
types, but the in vivo effects of this competition and
limiting amounts of RXR protein remain unclear [Jow and
Mukherjee, 1995].
PPARα knockout phenotype
PPARα knockout mice were generated by the Gonzalez
group [Lee et al., 1995].These mice have demonstrated
unequivocally that PPARα is indeed the bona fide
receptor responsible for mediating the pleiotropic
responses induced by synthetic peroxisome proliferators
[Lee et al., 1995]. In this knockout mouse model, the
ligand binding domain was disrupted by homologous
recombination. Mice homozygous for the mutation did
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with no detectable gross phenotypic defects [Lee et al.,
1995]. PPARα null mice display normal basal levels of
the inducible peroxisomal β-oxidation enzymes in liver,
but generally lower levels of mitochondrial fatty acid
metabolizing enzymes [Aoyama et al., 1998]. PPARα
knockout mice do not reveal PP-induced pleiotropic
responses when challenged with the classical peroxisome
proliferators, clofibrate and Wy-14,643 [Lee et al., 1995].
Subsequently, it was shown that PPARα knockout mice
fail to develop liver tumors when chronically exposed to
these PPARα ligands, indicating that PP-induced
hepatocarcinogenesis is receptor mediated, as previously
proposed [Gonzalez and Shah, 2008; Hays et al., 2005;
Peters et al., 1997; Rao and Reddy, 1987]. In essence,
these observations clearly established that PPARα is the
central player in mediating the pleiotropic responses of
peroxisome proliferators [Lee et al., 1995]. Numerous
studies with PPARα null mice during the past 15 years
have demonstrated the critical roles played by this
receptor in energy metabolism, hepatic steatosis,
inflammation, cardiac pathophysiology, cell cycle
alterations and hepatocarcinogenesis [Lefebvre et al.,
2006].
PPARα repressors and coactivators
Transcriptional activation of genes is a complex process,
which involves the participation of many transcription
coregulators [Glass and Rosenfeld, 2000]. PPARs, like
other nuclear receptors, interact with coactivators such
as SRC-1 (steroid receptor coactivator-1) [Onate et al.,
1995; Zhu et al., 1996], or corepressors such as N-CoR
(nuclear corepressor) [Chen and Evans, 1995; Dowell et
al., 1999], and SMRT (silencing mediator for retinoid and
thyroid hormone receptors) [Chen and Evans, 1995;
Dowell et al., 1999; Hu and Lazar, 1999].
PPARα-interacting coactivators and corepressors
augment or repress, respectively, the PPARα
transactivation activity [Feige et al., 2006;Yu and Reddy,
2007; Zoete et al., 2007]. Since the cloning of SRC-1
[Onate et al., 1995] 15 years ago, over 300
coactivators/coregulators have been identified, with new
members still being added to this expanding spectrum
[Lonard and O'Malley, 2006]. PPARα is known to interact
with some of these coregulators (Table 1).These include
CBP/p300, three members of the SRC/p160 family,
PBP/MED1 (PPAR-binding
protein/TRAP220/DRIP205/mediator subunit 1),
PRIP/NCoA6 (ASC2/RAP250/TRBP/NRC) [Zhu et al.,
2000a], PRIC285, PRIC295, PRIC320, PGC-1α, and
PGC-1β, as well as coactivator-associated proteins PIMT
(NCoA6IP) and CARM-1 (Table 1).The
PPARα-interacting coregulator (PRIC) complex isolated
from rat liver nuclear extracts reveals the presence of
many of these coregulators, presumably forming one
mega complex [Surapureddi et al., 2002].This diversity
raises several issues about the evolutionary importance
of the versatility and complexity of coregulatory molecules,
their relative abundance in various cell types, and their
affinity for a given nuclear receptor in orchestrating
transcription in gene-, cell-, and developmental
stage-specific transcription.
In the absence of a specific ligand, PPARα interacts with
corepressors NCoR and SMRT, but the importance of
this interaction for PPARα action is not well understood
[Feige et al., 2006]. Homozygous deletion of NCoR or
SMRT in mice is embryonic lethal, indicating that they
cannot fully compensate for each other during
development [Ghisletti et al., 2009; Jepsen et al., 2008;
Jepsen et al., 2000]. Furthermore, another corepressor,
the Receptor Interacting Protein 140 (RIP140), which can
interact with PPARα, is known to repress the activity of
NRs by competing with coactivators and by recruiting
downstream effectors such as histone deacetylases
(HDACs) [White et al., 2004]. Interestingly, the phenotype
of RIP140 knockout mice suggests a role for this
corepressor in PPARα signaling, as these mice exhibit
resistance to high-fat diet-induced obesity resulting from
upregulation of genes involved in energy dissipation
[Leonardsson et al., 2004].
The binding of ligand to a nuclear receptor influences
first, the release of corepressors and beginning
recruitment of coactivator complexes, such as members
of the SRC-1/p160 family, which exhibit histone
acetyltransferase activity required to facilitate chromatin
remodeling. Subsequent docking of other coregulators,
either singly, or as preassembled multisubunit protein
complexes, including mediator complex (MED), facilitates
interaction of ligand-activated receptor with RNA
polymerase and the general basal transcription machinery
to enhance the transcription of a specific set of genes
[Dotson et al., 2000; Glass and Rosenfeld, 2000; Shang
et al., 2000]. As indicated above, coactivators contain an
LXXLL motif that forms two turns of α-helix and binds to
a hydrophobic cleft on the surface of the nuclear receptor
[Voegel et al., 1998]. Data on the identification and
characterization of coactivators have been derived mostly
from in vitro observations, but there is a paucity of
information about the in vivo cell- and gene-specific
functional roles of individual coactivators [Yu and Reddy,
2007].
Coactivator gene-knockout mice: PPARα
signaling requires PBP/MED1
Gene knockout mouse models have established that
some of the coactivators are essential for embryonic
growth and survival, while others are not critical for mouse
embryogenesis [Reddy et al., 2006;Yu and Reddy, 2007].
For example, disruption of the PBP/MED1 gene results
in embryonic lethality in the mouse around gestational
day 11.5 [Crawford et al., 2002; Ito et al., 2000; Landles
et al., 2003; Zhu et al., 2000b]. Likewise, germ-line
deletion of the PRIP/ASC2/NRC/RAP250/NCoA6 gene
[Antonson et al., 2003; Qi et al., 2004], and the
PRIP-interacting protein PIMT/TGS1 (NCoA6IP) gene in
the mouse also result in embryonic lethality [Jia et al.,
2009b; Monecke et al., 2009]. In contrast, null mutation
of coactivators SRC-1 [Qi et al., 1999b], SRC-2 [Chopra
et al., 2008], and SRC-3, PGC-1, PRIC285 [Viswakarma
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et al., 2009], and CARM1 result in a viable phenotype
with or without overt functional changes.
Studies on the role of germ-line deletion of coactivators
SRC-1, SRC-2, and SRC-3 in the mouse revealed that
none of these are essential for PPARα ligand-induced
pleiotropic responses in liver ([Qi et al., 1999b] and Jia,
Y., Xu, J., and Reddy, J.K., unpublished observations).
These p160 family members are among the coactivators
considered important for nuclear receptor function, but
the in vivo results indicate their redundancy at least for
PPARα function in liver [Qi et al., 1999b]. It is likely that
other coactivators with histone acetyltransferase activity
may be adequate to facilitate chromatin remodeling in
the absence of SRC-1 and other members of the p160
family [Qi et al., 1999b]. Further studies are needed to
ascertain the effects of loss of two or more members of
this p160 family in PPARα function. Combined loss of
p/CIP/SRC-3 and SRC-1 function has been shown to
lead to a specific block in brown fat development, in part
due to a failure of induction of PPARγ target genes [Wang
et al., 2006]. Loss of both p/CIP/SRC-3 and SRC-1 also
leads to increased food intake on both regular chow and
a high-fat diet, indicating excess energy burning [Wang
et al., 2006].Whether loss of these two coactivators
results in strongly increased energy expenditure by
regulating PPARα- [Reddy and Hashimoto, 2001; Reddy
and Rao, 2006] and PPARβ/δ-dependent transcriptional
activities [Wang et al., 2003] remains to be investigated.
To study the cell- and gene-specific functions of
coactivator genes such as PBP/MED1 and PRIP/NCoA6,
which when germ-line disrupted, lead to embryonic
lethality in the mouse, it becomes necessary to generate
conditional null mice using the Cre-loxP strategy [Jia et
al., 2005; Jia et al., 2004; Jia et al., 2009a; Matsumoto
et al., 2007; Sarkar et al., 2007]. Conditional deletion of
PBP/MED1 gene in liver results in the abrogation of
PPARα ligand-induced pleiotropic effects, indicating that
PBP/MED1 is essential for PPARα signaling [Jia et al.,
2005; Matsumoto et al., 2007].When fed a diet containing
the PPARα ligands, Wy-14,643 or ciprofibrate, PBP/MED1
liver null mice revealed no peroxisome proliferation in
PBP/MED1-deficient hepatocytes [Jia et al., 2004].The
presence of an occasional PBP/MED1-positive hepatocyte
in these livers that escaped Cre-excision provided a
characteristic visual contrast, in that such cells displayed
the expected response to PPARα ligands, whereas the
response of PBP/MED1-deficient hepatocytes was similar
to that observed in cells that lacked PPARα [Jia et al.,
2004]. PPARα ligand-induced liver cell proliferation was
abolished in PBP/MED1 null hepatocytes and in these
livers, residual PBP/MED1-expressing cells displayed a
proliferative advantage [Jia et al., 2004; Matsumoto et
al., 2007]. Furthermore, PBP/MED1 is essential for partial
hepatectomy-related liver regeneration and PPARα ligand
Wy-14,643-induced receptor-mediated
hepatocarcinogenesis [Matsumoto et al., 2007].
PBP/MED1-deficient hepatocytes also fail to give rise to
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carcinogen diethylnitrosamine [Matsumoto et al., 2010].
Deletion of the PBP/MED1 gene in liver also abolished
the responses induced by constitutive androstane
receptor (CAR) activators, phenobarbital or 1,
4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP)
and of acetaminophen-induced hepatotoxicity [Jia et al.,
2005; Jia et al., 2009a]. In contrast, liver conditional
knockout of the PRIP/NCoA6 gene had no effect on
PPARα and CAR signaling in liver [Sarkar et al., 2007].
Mice with floxed PBP/MED1 [Jia et al., 2005; Jia et al.,
2009a; Matsumoto et al., 2007], PRIP/NCoA6 [Antonson
et al., 2003; Qi et al., 2004], PIMT/TGS1/NCoA6IP [Jia
et al., 2009b], PRIC285 [Viswakarma et al., 2009]; and
PRIC320 (Viswakarma, N. and Reddy, J.K., unpublished
observation) alleles should serve as valuable tools for
conditional gene disruption in cells of interest to further
evaluate the functional roles of PPARα.
PPARα functions
PPARα and energy burning
Obesity, resulting from increased consumption of
energy-rich foods high in saturated fats and sugars, and
reduced physical activity, has reached epidemic
proportions globally, with more than 1 billion adults
overweight [WHO, 2006].When consumption of energy
far exceeds the combustion of calories, there is increased
deposition of long-chain fatty acids, principally in the form
of triglycerides in adipose and other tissues leading to
obesity [Evans et al., 2004]. All three members of the
PPAR subfamily of nuclear receptors have been shown
to participate in energy metabolism in that PPARα and
PPARβ/δ function mostly as catabolic regulators of energy
expenditure, while PPARγ regulates anabolic metabolism
in that it plays a role in energy storage [Chawla et al.,
2001; Chawla et al., 1994; Cook et al., 2000; Evans et
al., 2004; Krey et al., 1997;Tontonoz et al., 1994].
The liver is a central player in the whole body energy
homeostasis by its ability to orchestrate fatty acid and
glucose metabolism. Hepatic lipid metabolism principally
involves three aspects: lipogenesis, oxidation of fatty
acids and secretion of lipids. Lipogenesis consists of de
novo fatty acid synthesis and subsequent conversion of
these fatty acids into triglycerides. In the liver, lipogenesis
is regulated by transcription factors, sterol regulatory
element-binding protein (SREBP-1c), carbohydrate
response-element binding protein (ChREBP) and PPARγ
[Browning and Horton, 2004; Horton et al., 2002;Wang
et al., 2003;Yu et al., 2003]. SREBP-1c regulates the
expression of constellations of glycolytic and lipogenic
genes, including stearoyl CoA desaturase (Scd-1) and
fatty acid synthase (Fas) [Hebbachi et al., 2008; Horton
et al., 2002; Reddy and Rao, 2006]. Emerging evidence
suggests that PPARα also influences lipogenesis by
increasing the transcription of Scd-1 and other lipogenic
genes by regulating the primary transcription factors
SREBP-1c and liver X receptor α (LXRα) [Hebbachi et
al., 2008]. It is suggested that PPARα participates in the
generation of an endogenous LXRα ligand, since a
synthetic, non-steroidal ligand of LXRα has been found
effective in the induction of lipogenic genes in mice
deficient in PPARα [Hebbachi et al., 2008]. However, the
role of PPARα in lipogenesis, albeit modest, is intriguing,
as it appears paradoxical to the well-known role of this
transcription factor in the regulation of fatty acid oxidation
[Reddy and Hashimoto, 2001].The involvement of PPARα
in lipogenesis may suggest a fail-safe compensatory
mechanism for the removal of important fatty acids, for
example, during starvation [Hebbachi et al., 2008].
Liver plays an important role in fatty acid oxidation and
this catabolic energy burning is regulated by PPARα
[Reddy and Hashimoto, 2001; Reddy and Rao, 2006].
Oxidation of fatty acids occurs in three subcellular
organelles, with the bulk of β-oxidation confined to
mitochondria and peroxisomes, while CYP4A-catalyzed
ω-oxidation takes place in the endoplasmic reticulum [Rao
and Reddy, 2004; Reddy and Hashimoto, 2001]. Some
of the key enzymes involved in these three fatty acid
oxidation systems possess PPRE elements and are
regulated by PPARα, though PPARβ/δ has also been
shown to regulate some of these genes [Desvergne and
Wahli, 1999; Reddy and Chu, 1996; Reddy and
Hashimoto, 2001; Sanderson et al., 2009; van der Meer
et al., 2010;Varanasi et al., 1996]. Fatty acids are
converted into acyl-CoAs prior to oxidation.
Mitochondrial β-oxidation is primarily involved in the
oxidation of the major portion of the short-(<C8),
medium-(C8-C12) and long-(C12-C20) chain fatty acids,
and in the process, constitutes the primary source of
energy derived from fatty acids [Reddy and Hashimoto,
2001].The PPARα-regulated enzymes, long chain
acyl-CoA synthetases and carnitine palmitoyl
transferase-1, are essential, respectively, for generating
fatty acyl-CoA, and facilitating the entry of fatty acyl
carnitine into mitochondria [Coleman et al., 2002].The
first step in mitochondrial β-oxidation is comprised of
α-β-dehydrogenation of the fatty acyl-CoA ester by a
family of four chain length specific straight chain acyl-CoA
dehydrogenases [Hashimoto, 1999; Reddy and
Hashimoto, 2001].These include very-long chain, medium
chain and short chain enzymes. A heterotrimeric protein,
exhibiting 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA
dehydrogenase, and 3-keto acyl-CoA thiolase activities,
participates in the second, third and fourth steps in the
mitochondrial β-oxidation pathway [Hashimoto, 1999;
Reddy and Rao, 2006]. Mitochondrial β-oxidation results
in the progressive shortening of fatty acids into acetyl-CoA
subunits.These either condense into ketone bodies to
serve as oxidizable energy substrates for extrahepatic
tissues, especially during starvation, or enter into the
tricarboxylic acid cycle for further oxidation to water and
carbon dioxide [Reddy and Hashimoto, 2001; Reddy and
Rao, 2006].
Peroxisomal β-oxidation is streamlined toward the
metabolism, almost exclusively, of very long straight-chain
fatty acids (>C20), 2-methyl branched fatty acids (e.g.,
pristanic acid that is generated by α-oxidation of the
3-methyl-branched fatty acid phytanic acid), prostanoids,
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and trihydroxycoprostanoic acids [Ferdinandusse et al.,
2009; Jia et al., 2003]. Substrates for peroxisomal
β-oxidation are less abundant and relatively more toxic,
and they are not processed by the mitochondrial
β-oxidation system [Reddy and Rao, 2006]. However,
peroxisomal β-oxidation is required to shorten the chain
length of very long chain fatty acids and chain-shortened
acyl-CoAs are shunted to mitochondria for the completion
of β-oxidation [Reddy and Hashimoto, 2001].The
coordinate inducibility of peroxisomal β-oxidation system
enzymes by peroxisome proliferators in now well
established [Reddy and Hashimoto, 2001; Reddy et al.,
1986b] and this induction is regulated by PPARα
[Issemann and Green, 1990; Kliewer et al., 2001; Lee et
al., 1995].
Peroxisomal β-oxidation consists of four metabolic steps
and each metabolic conversion can be performed by at
least two different enzymes [Hashimoto, 1999; Reddy
and Hashimoto, 2001]. Some of these enzymes are
inducible by peroxisome proliferators, while others seem
refractive to induction by these PPARα ligands [Reddy
and Hashimoto, 2001]. Straight-chain fatty acyl-CoAs
serve as substrates for the classical inducible pathway,
whereas the second non-inducible β-oxidation enzyme
system acts on 2-methyl-branched fatty acyl-CoAs
[Hashimoto, 1999]. In the inducible PPARα-regulated
peroxisomal β-oxidation pathway, fatty acyl-CoA oxidase
1 (ACOX1) is responsible for the initial oxidation of
very-long-chain fatty acyl-CoAs to their corresponding
trans-2-enoyl-CoAs. On the other hand, the non-inducible
fatty acyl-CoA oxidase 2 (ACOX2) serves as the first step
in the metabolism of branched-chain fatty acyl-CoAs.The
second and third reactions in the inducible β-oxidation
system, hydration and dehydrogenation of enoyl-CoA
esters to 3-ketoacyl-CoA are catalyzed by a single
bifunctional enzyme enoyl-CoA
hydratase/L-3-hydroxyacyl-CoA dehydrogenase
(L-PBE/MFP1). Ketoacyl-CoAs generated by
L-PBE/MFP1 are then converted by 3-ketoacyl-CoA
thiolase (PTL) to acetyl-CoA and to an acyl-CoA that is
two carbon atoms shorter than the original molecule.The
shortened acyl-CoA reenters the β-oxidation cycle, and
this process repeats for about 5 cycles, resulting in the
removal of ten carbon atoms.The appropriately
chain-shortened acyl-CoAs are then transported to
mitochondria for the completion of β-oxidation [Hashimoto,
1999].
All three genes of this classical inducible peroxisomal
β-oxidation system (ACOX1, L-PBE/MFP1, and PTL) are
tightly regulated by PPARα. Of interest is that
L-PBE/MFP1 protein is induced abundantly in the livers
of rats and mice treated with peroxisome proliferators
and accounts in part for the increase in peroxisome
population [Jia et al., 2003; Reddy, 2004]. Although,
L-PBE/MFP1 is highly inducible by both synthetic and
natural PPARα ligands in liver, the functions carried out
by this enzyme can be also performed highly effectively
by the D-3-hydroxyacyl-CoA
dehydratase/D-3-hydroxyacyl-CoA dehydrogenase
(D-bi/multifunctional enzyme 2; D-PBE/MFP2)
[Hashimoto, 1999; Jia et al., 2003]. 3-ketoacyl-CoAs
generated by D-PBE/MFP2 of the non-inducible pathway
are cleaved by the third enzyme of this system, sterol
carrier protein X, which possesses thiolase activity
[Hashimoto, 1999].
In addition to mitochondrial and peroxisomal β-oxidative
processing, fatty acids are also oxidized by microsomal
ω-oxidation carried out by CYP4A enzymes that are
regulated by PPARα [Reddy and Hashimoto, 2001].The
first step of ω-hydroxylation of saturated and unsaturated
fatty acids occurs in the endoplasmic reticulum and the
resulting ω-hydroxy fatty acid is then dehydrogenated to
yield highly toxic dicarboxylic acids in the cytosol.
Dicarboxylic acids are converted to dicarboxylyl-CoAs
and enter peroxisomes for further metabolism by the
classical inducible β-oxidative enzymes [Ferdinandusse
et al., 2004; Reddy and Rao, 2006]. Dicarboxylic acids
are unique in that they serve as substrates for the
peroxisomal β-oxidation system and also as ligands for
PPARα [Hashimoto, 1999]. It would appear that
dicarboxylic fatty acids streamline their own metabolism
by inducing PPARα activation and thus regulating all
three fatty acid oxidation enzyme pathways [Reddy and
Hashimoto, 2001].
In summary, the PPARα regulates all three fatty acid
oxidation systems. Gene knockout mouse models have
provided evidence to indicate that substrates for
peroxisomal β-oxidation function as PPARα ligands to
enhance energy burning. In this regard, hyperactivation
of PPARα by pharmacological intervention might prove
to be useful as an adjuvant to exercise in combating
obesity in individuals who are refractory to modulating
energy consumption. PPARα ligands do not appear to
cause weight loss independent of PPARα activation.
PPARα and hepatic steatosis
Fatty liver disease is the most common liver disease, as
it encompasses a morphological spectrum of hepatic
steatosis and steatohepatitis that progresses to cirrhosis
and hepatocellular carcinoma [Reddy, 2001; Reddy and
Rao, 2006; Zafrani, 2004]. Fatty liver disease occurs
worldwide in those with excess alcohol consumption
(alcoholic fatty liver disease), and those who are obese
with or without added insulin resistance (non-alcoholic
fatty liver disease) [Crabb et al., 2004; Evans et al., 2004;
Hamaguchi et al., 2005; Reddy and Rao, 2006; Sozio
and Crabb, 2008]. Several metabolic and genetic
diseases that influence fatty acid metabolism also develop
fatty liver disease [Browning and Horton, 2004; Reddy
and Rao, 2006]. Fatty liver disease is the culmination of
increased energy uptake, increased hepatic lipogenesis,
decreased energy combustion and decreased hepatic
secretion of liver triglycerides. PPARα gene knockout
mice have provided valuable clues regarding the role of
this transcription factor in energy metabolism by liver.
By virtue of its unique ability to orchestrate fatty acid
oxidation, PPARα appears to play a significant role in the
pathogenesis of hepatic steatosis. First, as indicated
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lipogenic genes by regulating the primary transcription
factors SREBP-1c and liver X receptor α (LXRα)
[Browning and Horton, 2004; Hebbachi et al., 2008].
Second, in conditions for increased demand for fatty acid
oxidation, such as starvation, PPARα is essential for the
upregulation of some of the enzymes necessary for this
process, though PPARβ/δ has recently been shown to
be important in regulating some of these genes
independently of PPARα [Sanderson et al., 2009]. Under
fasted conditions, PPARα senses the lipid influx into the
liver and upregulates all three fatty acid oxidation systems
to burn the energy and minimize hepatic steatosis
[Hashimoto et al., 2000; Kersten et al., 1999; Leone et
al., 1999]. PPARα null mice are unable to efficiently
induce the expression of genes involved in the oxidization
of fatty acids released from adipose tissue. Accordingly,
PPARα-deficient mice exhibit hepatic steatosis,
hyperlipidemia and hypothermia [Hashimoto et al., 2000;
Kersten et al., 1999; Leone et al., 1999]. PPARα null mice
also develop severe steatohepatitis compared to wild-type
mice when maintained on a diet deficient in methionine
and choline [Ip et al., 2003]. Furthermore, upon treatment
with PPARα ligands there is an attenuation of
methionine-choline deficient diet-induced steatohepatitis
[Rao and Reddy, 2004].
PPARα null mice fed ethanol develop marked
hepatomegaly, steatohepatitis, and liver cell death and
proliferation, implying a role for decreased fatty acid
oxidation in mice deficient in this transcription factor
[Nakajima et al., 2004]. Furthermore, ethanol is known
to inhibit fatty acid oxidation and this is attributed to
ethanol inhibition of PPARα transcription [Sozio and
Crabb, 2008]. Hypo-activity of PPARα might play a role
in the severity of alcohol liver disease in the human. On
the other hand, it has been shown that PPARα activation
is essential for hepatitis C virus (HCV) core
protein-induced hepatic steatosis and hepatocellular
carcinoma in mice [Tanaka et al., 2008].
PPARα and hypolipidemic effects
PPARα ligands reduce VLDL production and enhance
the catabolism of TG-rich particles, which indirectly
decreases small dense LDL (sdLDL) particles, enhancing
the formation of HDL particles and hepatic elimination of
excess cholesterol [Lefebvre et al., 2006]. PPARα
upregulates lipoprotein lipase transcription in liver and
muscle and this leads to increased TG hydrolysis.
The activity of ApoC-III, which is an inhibitor of both LPL
activity and remnant clearance, is lowered by PPARα
agonists [Peters et al., 1997]. PPARα agonists induce
ABCA1 and SR-BI expression in macrophages. HDL
apolipoprotein genes apoA-I and apoA-II are activated
by PPARα by direct transcriptional control [Desvergne
and Wahli, 1999; Lefebvre et al., 2006; Peters et al.,
1997].Thus, PPARα activation by fibrates and other
compounds, elicits a global normolipidemic response, by
reducing TG-rich particle production, increasing their
lipolysis, and promoting HDL metabolism [Lefebvre et al.,
2006].
PPARα and inflammation
Evidence indicates that PPARα plays a beneficial role in
reducing inflammation. Activation of this receptor appears
to influence both acute and chronic inflammatory
disorders involving neutrophils and macrophages.
Leukotriene B4 (LTB4), a powerful chemotactic
inflammatory eicosanoid, is an endogenous PPARα ligand
(Figure 2). Like other PPARα ligands, it induces
transcription of genes of the β- and ω-oxidation pathways
that neutralize and degrade LTB4 itself to regulate the
inflammatory response [Devchand et al., 1996;
Ford-Hutchinson, 1990]. Absence of PPARα prolongs
the LTB4-induced inflammatory response [Devchand et
al., 1996]. Agents containing LTB4 or its precursor
arachidonic acid, when applied to the ears of PPARα
knockout and wild-type mice, showed that the
inflammatory response was significantly prolonged in
PPARα null mice, compared to the wild-type controls
[Devchand et al., 1996].These data established that
PPARα regulates the duration of the inflammatory
response, possibly through limiting cytokine expression
and by inducing genes that metabolize LTB4 [Devchand
et al., 1996]. Based on these observations, it is logical to
surmise that PPARα ligands exert potential
anti-inflammatory effects in modulating various
inflammatory processes such as atherogenesis and
hepatitis [Devchand et al., 1996; Ricote and Glass, 2007;
Staels et al., 2008; Zandbergen and Plutzky, 2007].
Macrophages are mediators of inflammation in the
vasculature and participate in the development of
atherosclerotic plaques [Schwartz et al., 1985]. In the
pathogenesis of atherosclerosis, PPARα activation could
result initially in reduced leukocyte adhesion to activated
endothelial cells of the arterial lumen, and subsequently
in inhibiting the formation of macrophage foam cells by
regulating expression of genes involved in reverse
cholesterol transport and reactive oxygen species output
[Chinetti et al., 2001; Zandbergen and Plutzky, 2007].
Accordingly, activation of PPARα may be beneficial in
curtailing the inflammatory response and, in particular,
the formation and progression of atherosclerotic plaques
by minimizing lipoprotein oxidative modifications.
PPARα ligands significantly reduce the levels of
pro-inflammatory cytokines such as interleukin-1 (IL-1),
tumor necrosis factor-α (TNF-α), cyclooxygenase-2
(COX-2), and inducible nitric oxide synthase (iNOS) by
inhibiting the translocation of the p65 subunit of nuclear
factor κ-B (NF-κB) and decreasing phosphorylation of
the c-jun subunit of AP-1 [Ramanan et al., 2008]. Loss
of PPARα-mediated gene transcription in PPARα null
macrophages resulted in enhanced MAPK
phosphorylation, leading to increased NF-κB [Crisafulli
and Cuzzocrea, 2009]. Several other studies have also
demonstrated a similar, important role for PPARα in
modulating inflammation in vascular endothelial cells,
cartilage and bone tissue, kidney, adipose tissue, and
glial cells in the central nervous system (CNS) [Kim et
al., 2009; Kono et al., 2009; Murakami et al., 2007; Poleni
et al., 2007; Still et al., 2008].These studies may point
toward potential new roles for PPARα and PPARα target
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inflammation such as atherosclerosis, joint disease, and
autoimmune disorders such as multiple sclerosis [Arzuaga
et al., 2007; Dushkin et al., 2007].
PPARα and liver cancer
The development of HCC in mice fed a diet containing
nafenopin, a potent peroxisome proliferator, was first
reported in 1976 [Reddy et al., 1976]. Subsequently,
several hypolipidemic compounds and plasticizers such
as DEHP and DEHA have also been shown to induce
liver tumors in rats and mice [Kluwe et al., 1983; Rao and
Reddy, 1987; Reddy et al., 1980]. Rodents exposed to
peroxisome proliferators develop hepatomegaly, largely
due to the early hyperplastic and hypertrophic growth of
hepatocytes [Reddy et al., 1980; Reddy and
Krishnakantha, 1975; Reddy et al., 1979].With chronic
exposure, hepatic adenomas and hepatocellular
carcinomas develop in these rodents [Rao and Reddy,
1996; Reddy et al., 1980; Reddy et al., 1976].The latency
period and the incidence of liver tumors appear to
correlate well with the effectiveness of a given compound
to induce peroxisome proliferation-associated pleiotropic
responses [Rao and Reddy, 1996]. Phenotypic features
of peroxisome proliferator-induced liver tumors differ from
those induced by classic genotoxic hepatocarcinogens
[Rao and Reddy, 1996]. Since peroxisome proliferators
are neither DNA damaging nor mutagenic, it was
proposed that these compounds constitute a novel class
of nongenotoxic hepatocarcinogens and this concept laid
the foundation for the receptor-mediated
hepatocarcinogenesis [Rao and Reddy, 1987; Reddy et
al., 1980; Reddy and Lalwani, 1983;Yeldandi et al.,
2000].
Peroxisome proliferators do not directly cause genetic
damage. It became increasingly evident that
hepatocarcinogenicity is due to metabolic alterations
resulting from sustained receptor activation that contribute
to oxidative stress induced DNA damage in liver [Peters
et al., 2005; Rao and Reddy, 1987; Reddy and Lalwani,
1983; Rusyn et al., 2004;Yeldandi et al., 2000]. In normal
liver, hydrogen peroxide is produced as a byproduct of
many oxidative reactions [Yeldandi et al., 2000]. Of these,
the catabolism of very long chain fatty acids, resulting
from massive induction of the peroxisomal fatty acid
oxidation system by peroxisome proliferators, has
received considerable attention in peroxisome
proliferator-induced liver carcinogenesis [Nemali et al.,
1988; Reddy et al., 1982]. Peroxisomal catalase degrades
hydrogen peroxide in normal liver, but in livers with
peroxisome proliferation catalase expression increases
~2- to 5-fold in contrast to disproportionately large
increases in hydrogen peroxide producing acyl-CoA
oxidase and microsomal ω-oxidation enzymes [Chu et
al., 2004; Nemali et al., 1988;Yeldandi et al., 2000].This
imbalance between the expression of enzymes capable
of producing- and degrading- hydrogen peroxide and
other reactive oxygen species in hepatocytes contribute
to oxidative stress, lipid peroxidation and oxidative DNA
damage [Rao and Reddy, 1987].These changes influence
lipofuscin accumulation, a product of the oxidation of
unsaturated fatty acids, as well as hepatocellular
proliferation [Peters et al., 2005; Rao and Reddy, 1996;
Reddy et al., 1982]. DNA damage through oxidative stress
and hepatocellular proliferation, together, are considered
as possible mechanisms responsible for the development
of hepatocellular carcinomas in rodents chronically
exposed to peroxisome proliferators [Peters et al., 2005;
Rao and Reddy, 1987; Reddy, 2004; Reddy et al., 1980].
Consistent with this concept is a concordant marked
induction in the liver of genes specific for the long-patch
base excision DNA repair following exposure to PPARα
ligand, Wy-14,643 [Rusyn et al., 2004]. Long-patch base
excision DNA repair is a predominant pathway that
removes oxidized DNA lesions [Rusyn et al., 2004]. It is
evident that DNA-damaging oxidants are generated by
enzymes induced after activation of PPARα, such as
those involved in fatty acid oxidation [Rusyn et al., 2004].
Based on these observations, it is concluded that chronic
exposure to synthetic peroxisome proliferators results in
sustained activation of PPARα and transcriptional
activation of PPARα responsive genes that affect
intermediary metabolism in liver [Reddy and Chu, 1996;
Reddy and Hashimoto, 2001].These metabolic changes,
along with the anti-apoptotic effects of PPARα activation,
contribute to oxidative DNA damage and increased
hepatocellular proliferation leading to liver cancer
development [Chen et al., 2009; Peters et al., 2005;
Reddy and Chu, 1996].
Levels of regulation of PPARα
transcriptional activity
Although it has been well-demonstrated that peroxisome
proliferation and liver cancer develop in rodent models,
it is not clear that chronic administration of PPARα ligands
leads to tumorigenesis in humans. However, many factors
may contribute to this variability seen in species- and
cell-specific responses to PPARα ligands.The levels of
regulation of PPARα-induced responses (Figure 3)
include: the potency of specific exogenous and
endogenous PPARα ligands to activate PPARα [Fan et
al., 1998; Reddy et al., 1976], differential expression of
the PPARα and its heterodimerizing partner RXR [Palmer
et al., 1998], species differences in the promoter regions
of PPARα target genes [Reddy and Chu, 1996],
differential expression of certain coactivator proteins
necessary for PPARα-mediated transactivation and
differing expression levels and activity of PPARα target
genes [Jia et al., 2004;Yu and Reddy, 2007].
PPARα ligands show an intrinsic difference in their
capability to induce maximal PPARα activation and
peroxisome proliferation. Male F344 rats require feeding
of DEHP at a 2% (w/w) dietary level for 30 days in order
to achieve a significant degree of hepatomegaly and
peroxisome proliferation, while rats fed for the same
period on a diet containing only 0.01% ciprofibrate show
a significant increase in liver to body weight ratio [Reddy
et al., 1986a]. Ciprofibrate is more effective at inducing
the classical peroxisome proliferative response when
compared to phthalate ester plasticizers such as DEHP.
Furthermore, it should be noted that hepatic peroxisome
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Review Pleiotropic responses of PPARαFigure 3.  Levels of regulation of PPARα-mediated transcription. Diagram illustrating the different factors which regulate the ability of PPARα
to activate or repress transcription of target genes. Five major levels of regulation are: (1) the ligand, (2) the receptor expression, (3) the promoter, (4)
the coactivator proteins and (5) the expression of target genes.
proliferation is inducible in the livers of several species
including cats, chickens, pigeons and the nonhuman
primates such as rhesus and cynomologus monkeys by
ciprofibrate at dose levels that exceed therapeutic levels
[Lalwani et al., 1985; Reddy et al., 1984]. It would appear
that induction of peroxisome proliferation, in part, can be
dose-dependent, but not a species-specific phenomenon.
Tissue levels of expression of the PPARα receptor may
help explain the differences seen in response to treatment
with PPARα agonists. In the mouse, liver, kidney and
heart use fatty acid β-oxidation as a source of fuel. In
these tissues, the basal levels of mitochondrial β-oxidation
enzymes are similar. However, liver shows a much higher
degree of induction of PPARα-regulated fatty acid
oxidation enzymes than kidney or heart [Cook et al.,
2000]. PPARα levels appear to be lower in human livers,
as compared to rodent livers, and have been proposed
to account for reduced response of human liver to
peroxisome proliferation [Palmer et al., 1998]. Since these
estimates were from post mortem livers, data on freshly
obtained liver biopsy samples will be required for reliable
comparison [Palmer et al., 1998; Reddy, 2004].
Adenoviral overexpression of human PPARα in
PPARα-null mouse liver restored peroxisome
proliferator-induced pleiotropic responses in liver,
including peroxisome proliferation, induction of PPARα
target genes and liver cell proliferation [Yu et al., 2001].
The PPARα transactivational response is also regulated
by the nature of the PPRE sequence present in the
promoter region of responsive genes. PPARα may
regulate gene activity in conjunction with other
transcription factors such as CCAAT/enhancer-binding
protein (C/EBP), sterol regulatory element binding protein
1 (SREBP1), TATA-binding protein (TBP) and members
of the signal transducer and regulator of transcription
(STAT) family [van der Meer et al., 2010].The presence
or absence of motifs which bind these other transcription
factors in the promoter regions of PPARα target genes
had a significant influence on the ability of PPARα to
transactivate or transrepress expression of those genes.
Species differences in the promoter regions of PPARα
target genes may account for some of the differences
observed in response to treatment with PPARα ligands.
As previously discussed, coactivator proteins are required
for effective transactivation of target genes by PPARα.
The protein, PBP/MED1, when disrupted in mouse liver,
results in the abrogation of peroxisome proliferation and
other pleiotropic effects of treatment with PPARα ligands
[Jia et al., 2004; Matsumoto et al., 2007].The degree of
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PBP/MED1, and the particular milieu of coactivators
expressed in a particular tissue, organism, or species
may therefore also contribute to the variable species
response to treatment with PPARα ligands.
Recently, it has been shown that activation of PPARα
represses the expression of the let-7C miRNA, which in
turn releases the repression of c-myc expression [Shah
et al., 2007]. Interestingly, mice expressing the human
PPARα protein do not show this repression of the let-7C
miRNA [Yang et al., 2008]. Accordingly, these mice also
do not exhibit hepatocellular proliferation or development
of tumors [Gonzalez and Shah, 2008; Morimura et al.,
2006; Shah et al., 2007].This induced expression of
c-myc protein is proposed to be the mechanism
contributing to PPARα ligand-induced hepatocellular
proliferation [Shah et al., 2007]. Increased cell proliferative
stimulus mediated by PPARα ligands in an intense
oxidative stress inducing environment in livers with
peroxisome proliferation, could act in concert and
contribute to the development of liver tumors.
Nonetheless, the level of human PPARα expression may
be an issue for consideration in humanized PPARα mice,
since adenoviral overexpression of human PPARα in
PPARα-null mice showed robust liver cell proliferation in
response to a synthetic PPARα ligand [Yu et al., 2001].
Accordingly, sustained activation of PPARα by synthetic
ligands is hepatocarcinogenic, as observed in rodent
models [Reddy and Chu, 1996].
Additionally, PPARα activity is influenced by the ability
of target genes, such as ACOX1 to efficiently metabolize
and thus remove endogenous ligands in hepatocytes. In
ACOX1 null mouse livers, PPARα activity is dramatically
increased as a result of the accumulation of
unmetabolized, endogenous ligands [Cook et al., 2000;
Fan et al., 1998;Yeldandi et al., 2000]. As a result,
species differences in the expression of PPARα target
genes may also contribute to species-specific responses
to treatment with PPARα ligands. ACOX1 null mouse
livers display the hallmarks of PPARα activation such as
hepatocellular regeneration accompanied by profound
generalized spontaneous peroxisome proliferation, and
increased mRNA levels of genes that are regulated by
PPARα, which ultimately lead to liver tumor development
[Fan et al., 1998]. Although ACOX1, a major hydrogen
peroxide generating enzyme in peroxisomes, is absent
in these livers, there appear to be other sources that may
contribute to oxidative stress in liver such as cytochrome
P450 family proteins induced by activated PPARα [Fan
et al., 1998; Reddy and Hashimoto, 2001;Yeldandi et
al., 2000].These CYP4A proteins typically catalyze the
addition of oxygen to a variety of substrate molecules
and may produce reactive oxygen as a by-product
[Reddy, 2004; Reddy and Hashimoto, 2001;Yeldandi et
al., 2000].Thus, it would be essential to consider that
ACOX1 is not the only source of oxidative stress in
PPARα-activated livers. Expression of long-patch base
excision DNA repair genes was found to be upregulated
significantly in livers of naïve ACOX1-null mice and was
increased similarly to the effect of WY-14,643 [Rusyn et
al., 2004].These observations strongly support that
sustained activation of PPARα in liver, either by synthetic
or natural ligands, leads to endoplasmic reticulum and
oxidative stress. Liver tumors that develop in ACOX1 null
livers exhibit similar cDNA profiles as tumors resulting
from long-term treatment with PPARα ligands, but not
similar to tumors resulting from treatment with
diethylnitrosamine, a genotoxic mutagen [Fan et al., 1998;
Meyer et al., 2003].These observations further support
the novel nature of PPARα ligand-induced
hepatocarcinogenesis.
PPARα polymorphism
Genetic variation and polymorphism of PPARα in the
human have been under intensive study [Carlberg and
Dunlop, 2006].To date, at least 14 polymorphisms of
PPARα have been reported (Figure 1) [Naito et al., 2006]
and include P22R, D140Y [Hara et al., 2001], R127Q
(rs1800204), R131Q [Sapone et al., 2000], L162V
(rs1800206), R178G [Nielsen et al., 2003], V227A
(rs1800234), A268V (rs1042311), D304N (rs1800242),
G395A (rs2229245), D409T (rs1800243), Q413L
(rs9615759), D140N and G395E [Naito et al., 2006].
Some of these variations were reportedly associated with
human lipid metabolic changes. For example,
PPARα-V227A is a major polymorphism in the Japanese
population [Naito et al., 2006]. Its activity may be greater
than that of wild-type PPARα, but is decreased by
increased alcohol consumption, suggesting that alcoholic
liver injury may affect the activity of this receptor [Naito
et al., 2006]. Among the 4,248 subjects from 3 ethnic
groups (2,899 Chinese, 761 Malay and 588 Asian Indians)
genotyped for polymorphisms at the PPARA locus, allele
frequencies for the V227A mutation were 0.04 in Chinese,
0.006 in Malays and 0.003 in Asian Indians [Chan et al.,
2006].This polymorphism is associated with lower serum
concentrations of total cholesterol and triglycerides in
Chinese women.The V227A polymorphism is believed
to modulate the association between dietary
polyunsaturated fatty acid intake and serum high density
lipoprotein concentration.These observations suggest
that genetic variation of PPARα may determine the
response to changes in dietary PUFA intake [Chan et al.,
2006]. Furthermore, L162V polymorphism in the PPARα
gene, first identified in the Caucasian population [Sapone
et al., 2000;Vohl et al., 2000], was associated with
increased levels of serum apolipoprotein B and LDL
cholesterol.The L162V polymorphism in PPARα may
determine the response to PPARα ligands [Bosse et al.,
2002].The PPARα-L162V polymorphism alone or in
interaction with dietary fat intake is associated with
components of the metabolic syndrome and may
contribute to variability in plasma lipoprotein and lipid
response after modification of the dietary polyunsaturated
to saturated fatty acids ratio [Paradis et al., 2005;
Robitaille et al., 2004; Sapone et al., 2000;Vohl et al.,
2000].
Conclusions
Studies with a structurally diverse group of chemicals
designated as peroxisome proliferators laid the foundation
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named peroxisome proliferator-activated receptor (PPAR)
with three members: PPARα, PPARβ/δ and PPARγ. Of
these, PPARα plays a critical role in fatty acid oxidation
and is thus responsible for energy expenditure. Sustained
activation of PPAR leads to the development of liver
tumors in rats and mice, whereas PPARα deficiency leads
to impaired response to fatty acid influx into liver and
contributes to hepatic steatosis. Studies with gene
knockout mouse models have yielded information on
putative endogenous PPARα ligands that are either
generated or degraded by certain enzymes during
intermediary metabolism. Several nuclear receptor
coactivators have been noted to interact with PPARα,
but studies to-date indicate that the coactivator
PBP/MED1 is essential for PPAR target gene activation,
liver cell proliferation and liver tumorigenesis. As for future
challenges, it remains to be determined the extent and
nature of other endogenous PPAR agonists and other
coactivators that influence PPARα function. Such
information may provide clues for therapeutic intervention
to enhance energy utilization, minimize the adverse
effects of both alcoholic and nonalcoholic fatty liver
disease and modulate liver cell proliferation.
Supplementary Material
Supplementary File 1: Known target genes of PPARα.
Supplementary File 2:Bibliography for the known target
genes of PPARα table above.
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